Media contributions
1Media contributions
Title Semaglutide: FDA approves weight loss jab to treat severe liver disease Degree of recognition National Media name/outlet The BMJ Media type Print Country/Territory United Kingdom Date 21/08/25 Description Akheel Syed, a consultant in diabetes and endocrinology and honorary clinical chair at the Manchester Academic Health Science Centre, told The BMJ that the FDA approval was an “exciting development.”
He added that the accelerated approval was unsurprising. “With only one other drug, resmetirom, specifically approved for the treatment of MASH, the new approval of semaglutide, a drug from a well known and widely used class of medications for type 2 diabetes and obesity, is most welcome.”
However, he added that a lack of specific diagnostic criteria from the FDA meant that further guidance for clinicians would be “essential.”Producer/Author Kate Bowie, The BMJ URL https://doi.org/10.1136/bmj.r1788 Persons Akheel Syed